Update shared on06 Aug 2025
Fair value Increased 15%Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11.
What's in the News
- Alcon Inc. agreed to acquire STAAR Surgical for $1.5 billion in cash ($28 per share), with the transaction expected to close in six to 12 months, subject to regulatory and shareholder approvals; deal anticipated to be accretive to earnings in year two.
- STAAR Surgical added to multiple Russell value-oriented benchmarks, including Russell 3000 Value, 2500 Value, 2000 Value, Small Cap Comp Value, 3000E Value, and corresponding indices, while being dropped from Russell 2000 Defensive and Russell 2000 Growth-Defensive indices.
- Deborah Andrews appointed as Chief Financial Officer, having previously served in key financial roles at STAAR and as Interim CFO since March 2025.
- Board authorized a $30 million share repurchase program valid for six months, to be funded from existing cash and operations.
Valuation Changes
Summary of Valuation Changes for STAAR Surgical
- The Consensus Analyst Price Target has significantly risen from $19.20 to $22.11.
- The Net Profit Margin for STAAR Surgical has significantly risen from 2.99% to 3.34%.
- The Discount Rate for STAAR Surgical has risen from 7.12% to 7.56%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.